JAK2 p.V617F detection and allele burden measurement in peripheral blood and bone marrow aspirates in patients with myeloproliferative neoplasms

Blood

Volumn 122, Issue 23, 2013, Pages 3784-3786

  Takahashi, Koichi ^a,b   Patel, Keyur P ^c   Kantarjian, Hagop ^a   Luthra, Rajyalakshmi ^b   Pierce, Sherry ^a   Cortes, Jorge ^a   Verstovsek, Srdan ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c Department of Hematopathology ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

JANUS KINASE 2;

ALLELE; ARTICLE; BONE MARROW BIOPSY; HUMAN; MAJOR CLINICAL STUDY; MYELOPROLIFERATIVE NEOPLASM; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY;

EID: 84891085587     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-07-515676     Document Type: Article

References (15)

1. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005; 352(17):1779-1790
2. Tefferi A, Thiele J, Orazi A, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood. 2007;110(4): 1092-1097
3. Vannucchi AM, Antonioli E, Guglielmelli P, Pardanani A, Tefferi A. Clinical correlates of AK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal. Leukemia. 2008;22(7):1299-1307
4. Tefferi A, Strand JJ, Lasho TL, et al. Bone marrow JAK2V617F allele burden and clinical correlates in polycythemia vera. Leukemia. 2007;21(9): 2074-2075
5. Vannucchi AM, Antonioli E, Guglielmelli P, et al. Clinical profile of homozygous JAK2 617V.F mutation in patients with polycythemia vera or essential thrombocythemia. Blood. 2007;110(3): 840-846
6. Tefferi A, Lasho TL, Schwager SM, et al. The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera. Cancer. 2006;106(3):631-635
7. Gattenlohner S, Peter C, Bonengel M, et al. Detecting the JAK2 V617F mutation in fresh and 'historic' blood and bone marrow. Leukemia. 2007;21(7):1599-1602
8. Lange T, Edelmann A, Siebolts U, et al. JAK2 p.V617F allele burden in myeloproliferative neoplasms one month after allogeneic stem cell transplantation significantly predicts outcome and risk of relapse. Haematologica. 2013;98(5): 722-728
9. Bench AJ, White HE, Foroni L, et al British Committee for Standards in Haematology. Molecular diagnosis of the myeloproliferative neoplasms: UK guidelines for the etection f JAK2 V617F and other relevant mutations. Br J Haematol. 2013;160(1):25-34
10. Larsen TS, Pallisgaard N, Møller MB, Hasselbalch HC. Quantitative assessment of the JAK2 V617F allele burden: equivalent levels in peripheral blood and bone marrow. Leukemia. 2008;22(1): 194-195
11. Swerdlow SH, International Agency for Research on Cancer. World Health Organization. WHO classification of tumours of haematopoietic and lymphoid tissues, 4th ed. Lyon, France: International Agency for Research on Cancer; 2008
12. Jelinek J, Oki Y, Gharibyan V, et al. JAK2 mutation 1849G>.T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia. Blood. 2005;106(10): 3370-3373
13. Alchalby H, Badbaran A, Zabelina T, et al. Impact of JAK2V617F mutation status, allele burden, and clearance after allogeneic stem cell transplantation for myelofibrosis. Blood. 2010; 116(18):3572-3581
14. Kröger N, Badbaran A, Holler E, et al. Monitoring of the JAK2-V617F mutation by highly sensitive quantitative real-time PCR after allogeneic stem cell transplantation in patients with myelofibrosis. Blood. 2007;109(3):1316- 1321
15. Jovanovic JV, Ivey A, Vannucchi AM, et al. Establishing optimal quantitative- polymerase chain reaction assays for routine diagnosisand tracking of minimal residual disease inJAK2-V617F-associated myeloproliferative neoplasms: a joint European eukemiaNet/ MPN&MPNr-EuroNet (COST action BM0902) study. Leukemia. 2013. Epub ahead of print